Conclusion: iTRAQ-based quantitative proteomic technology is efficiently applicable for protein identification and relative quantitation of proteomes of renal tissue. Differentially expressed proteome profiles of MePGN patients are determined. Further investigation of the molecular mechanism of the involved proteins may help to better understand the pathogenesis of MePGN and to discover novel biomarker candidates, which may enable the development of new approaches to diagnosis of MePGN.
PMID: 22641580 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)